Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Alopecia Areata
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Velsipity
Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
View on EMAVaccines, Pneumococcal
Renal Transplantation
Diabetes Mellitus
Major Depressive Disorder
Complicated Intra-abdominal Infections